2. Search Result
Search Result
Results for "

Hepatic fibrosis

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

6

Biochemical Assay Reagents

5

Peptides

3

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100438
    Hydronidone

    		Others Inflammation/Immunology
    Hydronidone is a pyridine derivative and an antifibrotic agent for hepatic fibrosis .
    Hydronidone
  • HY-151481
    FXR antagonist 1

    		FXR Metabolic Disease
    FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC50=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .
    FXR antagonist 1
  • HY-133019
    ATX inhibitor 5

    		Phosphodiesterase (PDE) Inflammation/Immunology
    ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently .
    ATX inhibitor 5
  • HY-162147
    Nur77 modulator 3

    		mTOR Autophagy Inflammation/Immunology
    Nur77 modulator 3 (9e) can bind to Nur77 and inhibit TGF-β1-induced α-SMA and COLA1 expression in a Nur77-dependent manner. Nur77 modulator 3 induces Nur77 expression and enhances autophagic flux by inhibiting the mTORC1 signaling pathway in vitro and in vivo. Nur77 modulator 3 blocks the progression of hepatic fibrosis .
    Nur77 modulator 3
  • HY-P0299A
    LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)
    Maximum Cited Publications
    11 Publications Verification

    		 TGF-β Receptor Cancer
    LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .
    LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA)
  • HY-P0299
    LSKL, Inhibitor of Thrombospondin (TSP-1)
    Maximum Cited Publications
    11 Publications Verification

    		 TGF-β Receptor Cancer
    LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .
    LSKL, Inhibitor of Thrombospondin (TSP-1)
  • HY-154979
    Anti-hepatic fibrosis agent 2

    		Others Inflammation/Immunology
    Anti-hepatic fibrosis agent 2 (Compound 6k) is an orally active COL1A1 inhibitor. Anti-hepatic fibrosis agent 2 is an anti-fibrogenic agent targeting ewing sarcoma breakpoint region 1 (EWSR1) .
    Anti-hepatic fibrosis agent 2
  • HY-161139
    JAK1-IN-14

    		JAK Inflammation/Immunology
    JAK1-IN-14 (Compound 12a) is a potent and selective JAK1 inhibitor. JAK1-IN-14 inhibits JAK1 and JAK2 with an IC50 value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases .
    JAK1-IN-14
  • HY-149899
    VDR agonist 2

    		VD/VDR Others
    VDR agonist 2 (compound 16i) is a VDR (vitamin D receptor) agonist that can effectively inhibit TGF-β1-induced activation of hepatic stellate cells (HSC). VDR agonist 2 has significant anti-hepatic fibrosis effects both in vitro and in vivo .
    VDR agonist 2
  • HY-W753806
    Doxazosin hydrochloride

    UK 33274 hydrochloride

    		 Others Cardiovascular Disease
    Doxazosin hydrochloride (UK 33274 hydrochloride) is a compound used to inhibit hypertension and prostate hyperplasia, with activity that inhibits postsynaptic α1-adrenoceptors on vascular smooth muscle. Doxazosin hydrochloride can cause vasodilation, thereby reducing peripheral vascular resistance. Doxazosin hydrochloride was found to inhibit the proliferation and migration of hepatic stellate cells in a mouse liver fibrosis model. Doxazosin hydrochloride regulates fibrosis, autophagy, and apoptosis of hepatic stellate cells by activating the PI3K/Akt/mTOR signaling pathway. Doxazosin hydrochloride also blocks autophagic flux and induces apoptosis of hepatic stellate cells .
    Doxazosin hydrochloride
  • HY-47888
    PLN-1474

    		Integrin Inflammation/Immunology
    PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.
    PLN-1474
  • HY-121212
    Icosabutate

    		Others Metabolic Disease Inflammation/Immunology
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia  .
    Icosabutate
  • HY-N13208
    Stevia Powder

    		MMP TGF-beta/Smad Others
    Stevia Powder is a natural sweetener with antioxidant activity. Stevia Powder can downregulate pro fibrotic pathways in cirrhotic rats, including reduced hepatic myofibroblasts and decreased expression of matrix metalloproteinases MMP2 and MMP13, upregulate anti fibrotic molecule Smad7, prevent serum necrosis and elevated bile stasis markers, thereby inhibiting the development of liver fibrosis .
    Stevia Powder
  • HY-P3971
    H-Leu-Ser-Lys-Leu-OH

    		TGF-beta/Smad Inflammation/Immunology
    H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .
    H-Leu-Ser-Lys-Leu-OH
  • HY-N4215
    11(α)-Methoxysaikosaponin F

    		Others Inflammation/Immunology
    11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from Bupleurum marginatum Wall.ex DC(ZYCH) which is a promising therapeutic for liver fibrosis. 11(α)-Methoxysaikosaponin F has an IC50 of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6). Triterpenoid saponins have numerous targets, important network positions, and strong inhibitory activity .
    11(α)-Methoxysaikosaponin F
  • HY-124748A
    ENMD-1068 hydrochloride
    2 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Inflammation/Immunology
    ENMD-1068 hydrochloride is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 hydrochloride reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 hydrochloride also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 hydrochloride can be used in the study of endometriosis and liver fibrosis .
    ENMD-1068 hydrochloride
  • HY-124748
    ENMD-1068

    		Protease Activated Receptor (PAR) Apoptosis Inflammation/Immunology
    ENMD-1068 is a selective protease-activated receptor 2 (PAR2) antagonist. ENMD-1068 reduces hepatic stellate cell activation and collagen expression by inhibiting TGF-β1/Smad signaling. ENMD-1068 also inhibits the proliferation of endometrial cells and induces apoptosis of epithelial cells in the lesion. ENMD-1068 can be used in the study of endometriosis and liver fibrosis .
    ENMD-1068
  • HY-161506
    PDE1-IN-7

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE1-IN-7 (Compound 13h) is a selective inhibitor of bPDE1 (IC50= 10 nM). PDE1-IN-7 exhibits significant anti-fibrotic effects in a BDL-induced liver fibrosis rat model. PDE1-IN-7 can be used for research in liver fibrosis .
    PDE1-IN-7
  • HY-156119
    MLKL-IN-6

    		Mixed Lineage Kinase Necroptosis Metabolic Disease Cancer
    MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .
    MLKL-IN-6
  • HY-P1624
    Teduglutide
    1 Publications Verification

    ALX-0600

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide
  • HY-P1624A
    Teduglutide TFA

    ALX-0600 TFA

    		 Nuclear Hormone Receptor 4A/NR4A FXR Inflammation/Immunology
    Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
    Teduglutide TFA
  • HY-122179
    NUCC-555

    		TGF-β Receptor Inflammation/Immunology
    NUCC-555 is an activin antagonist. NUCC-555 interacts with Trp25, Trp28, Phe55, Tyr93, Lys103, and Asn107 in the Activin A binding pocket. NUCC-555 blocks Activin A-mediated hepatic stellate cells (HSCs) activation. NUCC-555 promotes liver regeneration and halts fibrosis progression in chronic liver disease models. NUCC-555 inhibits Activin A-mediated ovarian cell proliferation. NUCC-555 decreases FSH levels in ovariectomized mice .
    NUCC-555
  • HY-100450
    BML-111

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease Inflammation/Immunology Cancer
    BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2). BML-111 has antiangiogenic, antitumor and anti-inflammatory properties .
    BML-111
  • HY-151427
    TGFβ1-IN-1

    		TGF-β Receptor Inflammation/Immunology
    TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies .
    TGFβ1-IN-1
  • HY-129389
    Benzyl-α-GalNAc
    1 Publications Verification

    		 Others Cancer
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-FU (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .
    Benzyl-α-GalNAc
  • HY-163429
    J-1149

    		TGF-β Receptor p38 MAPK Inflammation/Immunology Cancer
    J-1149 is a potent ALK5 inhibitor, with an IC50 value of 0.017 μM. J-1149 also shows weak p38α MAP kinase inhibitory activity, with an IC50 value of 0.435 μM. J-1149 can be used for liver fibrosis research .
    J-1149
  • HY-112724
    Ivarmacitinib

    SHR0302

    		 JAK Apoptosis Inflammation/Immunology Cancer
    Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .
    Ivarmacitinib
  • HY-Y0682B
    Ethylenediaminetetraacetic acid tetrasodium
    5+ Cited Publications

    EDTA tetrasodium

    		 Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease
    Ethylenediaminetetraacetic acid (EDTA) tetrasodium is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid tetrasodium has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid tetrasodium decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid tetrasodium can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid tetrasodium can be used for coronary artery disease and neural system disease research .
    Ethylenediaminetetraacetic acid tetrasodium
  • HY-112724A
    Ivarmacitinib sulfate

    SHR0302 sulfate

    		 JAK Apoptosis Inflammation/Immunology Cancer
    Ivarmacitinib (SHR0302) sulfate is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects .
    Ivarmacitinib sulfate
  • HY-B1009
    Ethylenediaminetetraacetic acid trisodium salt
    5+ Cited Publications

    EDTA trisodium salt; Trisodium EDTA

    		 Ferroptosis Bacterial SOD Cardiovascular Disease Neurological Disease Cancer
    Ethylenediaminetetraacetic acid trisodium salt (EDTA trisodium salt; Trisodium EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid trisodium salt has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid trisodium salt decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid trisodium salt can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .
    Ethylenediaminetetraacetic acid trisodium salt
  • HY-Y0682A
    Ethylenediaminetetraacetic acid disodium dihydrate
    5+ Cited Publications

    EDTA disodium dihydrate

    		 Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease
    Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research .
    Ethylenediaminetetraacetic acid disodium dihydrate
  • HY-Y0682
    Ethylenediaminetetraacetic acid
    5+ Cited Publications

    EDTA

    		 Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease Cancer
    Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research .
    Ethylenediaminetetraacetic acid
  • HY-W105700
    Ethylenediaminetetraacetic acid sodium hydrate
    5+ Cited Publications

    EDTA sodium hydrate

    		 Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease
    Ethylenediaminetetraacetic acid (EDTA) sodium hydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid sodium hydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid sodium hydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid sodium hydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid sodium hydrate can be used for coronary artery disease and neural system disease research .
    Ethylenediaminetetraacetic acid sodium hydrate
  • HY-Y0682AR
    Ethylenediaminetetraacetic acid disodium dihydrate (Standard)

    		Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease Cancer
    Ethylenediaminetetraacetic acid (disodium dihydrate) (Standard) is the analytical standard of Ethylenediaminetetraacetic acid (disodium dihydrate). This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid (EDTA) disodium dehydrate is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid disodium dehydrate has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid disodium dehydrate decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid disodium dehydrate can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid disodium dehydrate can be used for coronary artery disease and neural system disease research [4] .
    Ethylenediaminetetraacetic acid disodium dihydrate (Standard)
  • HY-Y0682R
    Ethylenediaminetetraacetic acid (Standard)

    		Biochemical Assay Reagents Bacterial SOD Cardiovascular Disease Neurological Disease Cancer
    Ethylenediaminetetraacetic acid (Standard) is the analytical standard of Ethylenediaminetetraacetic acid. This product is intended for research and analytical applications. Ethylenediaminetetraacetic acid (EDTA) is a kind of metal chelating agent (binds to bivalent and trivalent metal cations, including calcium). Ethylenediaminetetraacetic acid has antibacterial, anti-inflammatory, antioxidant, anti-hypercalcemia and anticoagulant activities. Ethylenediaminetetraacetic acid decreases the metal ion-catalyzed oxidative damage to proteins, and allows maintenance of reducing environment during protein purification. Ethylenediaminetetraacetic acid can alleviate the liver fibrosis. Ethylenediaminetetraacetic acid can be used for coronary artery disease and neural system disease research [4] .
    Ethylenediaminetetraacetic acid (Standard)
  • HY-134988
    EDP-305

    		FXR Phosphatase Cytochrome P450 Inflammation/Immunology
    EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .
    EDP-305

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: